These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 32081779)

  • 21. Development of stealth liposome coencapsulating doxorubicin and fluoxetine.
    Ong JC; Sun F; Chan E
    J Liposome Res; 2011 Dec; 21(4):261-71. PubMed ID: 21226547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
    Arima H; Hagiwara Y; Hirayama F; Uekama K
    J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
    Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
    Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect.
    Ahmed KS; Changling S; Shan X; Mao J; Qiu L; Chen J
    J Liposome Res; 2020 Sep; 30(3):285-296. PubMed ID: 31223044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
    Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NIR-Laser-Controlled Drug Release from DOX/IR-780-Loaded Temperature-Sensitive-Liposomes for Chemo-Photothermal Synergistic Tumor Therapy.
    Yan F; Duan W; Li Y; Wu H; Zhou Y; Pan M; Liu H; Liu X; Zheng H
    Theranostics; 2016; 6(13):2337-2351. PubMed ID: 27877239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.
    Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S
    Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of Liposome Gel by Calcium Cross-Linking Induces the Long-Term Release of DOX to Improve the Antitumor Effect.
    Wang L; Wang Y; Ye Z; Yu Y; Wang C; Qiu L; Du X; Zhou S; Wang J; Jiang P
    Mol Pharm; 2024 May; 21(5):2394-2405. PubMed ID: 38647653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells.
    Haggag Y; Abu Ras B; El-Tanani Y; Tambuwala MM; McCarron P; Isreb M; El-Tanani M
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1655-1669. PubMed ID: 32841584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R; Mayer LD
    Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.